Form D · Biotechnology
Intervene Immune, Inc.
Manhattan Beach, CA · CIK 0001797564
Offering snapshot reported Dec 27, 2019 · SEC filing
- Reported sold
- $471K Indefinite offering
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 27, 2019 | Initial | $470,800 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-356563
Source: Form D, filed Dec 27, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Brooke | Director, Executive |
| Gregory Fahy | Director, Executive |
| Paul Hynek | Executive |
| Philip Kernan Jr. | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1601 N. Sepulveda Boulevard Suite 632
Manhattan Beach, CA, 90266
Manhattan Beach, CA, 90266